MedTrace Logo

Immune Response Following COVID-19 in Hemodialysis Patients

NCT05307601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2022-04-01

No results posted yet for this study

Summary

Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at high risk of a severe form of COVID-19.

This study aims to characterize the inflammatory and antiviral response during SarsCov2 infection in adult

Conditions

  • Dialysis; Complications
  • COVID-19
  • Cytokine Storm

Sponsors & Collaborators

  • AURA Paris

    lead OTHER

Principal Investigators

  • Maxime Touzot, MD, PhD · AURA Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-09-01
Completion
2021-10-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307601 on ClinicalTrials.gov